Interleukin-1: A new therapeutic target for ankylosing spondylitis?

Joint Bone Spine

Volumn 72, Issue 5, 2005, Pages 357-358

  Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Anakinra; Ankylosing spondylitis; Interleukin 1; Interleukin 1 receptor antagonist

Indexed keywords

INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANKYLOSING SPONDYLITIS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; INJECTION SITE REACTION; JOINT BIOPSY; THEORETICAL STUDY;

HUMANS; INTERLEUKIN-1; SPONDYLITIS, ANKYLOSING;

EID: 26244453187     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2004.10.013     Document Type: Editorial

References (13)

1. D. Wendling, and E. Toussirot Anti TNF-α therapy in ankylosing spondylitis Expert Opin Pharmacother 5 2004 1497 1507
2. D. Wendling Anti-TNFα therapy in spondyloarthropathy: deciding who to treat Joint Bone Spine 70 2003 401 403
3. J.M. Dayer The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis Joint Bone Spine 69 2002 123 132
4. M. Vazquez:Del:Mercado, A. Garcia-Gonzales, J.F. Munoz-Valle, T. Garcia-Iglesias, G. Martinez-Bonilla, Bernard, and G. Medina Interleukin 1β (IL-1β), IL-10, tumor necrosis factor-α and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis J Rheumatol 29 2002 522 526
5. C. Gabay, N. Cakir, F. Moral, P. Roux-Lombard, O. Meyer, and J.M. Dayer Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity J Rheumatol 24 1997 303 308
6. P. Claudepierre, J.C. Rymer, F.J. Authier, Y. Allanore, B. Larget-Piet, and R. Gherardi A relationship between TGF-β1 or IL-6 plasma levels and clinical features of spondyloarthropathies Br J Rheumatol 36 1997 400 401
7. J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, and H. Herbst Use of immunohistologic and in situ hybridization techniques in the examination of sacro iliac joint specimens from patients with ankylosing spondylitis Arthritis Rheum 38 1995 499 505
8. F. Mc:Garry, J. Neilly, N. Anderson, R. Sturrock, and M. Field A polymorphism within the interleukin 1 receptor antagonist (IL-1RA) gene is associated with ankylosing spondylitis Rheumatology 40 2001 1359 1364
9. M. Van:der:Paardt, J.B.A. Crusius, M.A. Garcia-Gonzales, P. Baudoin, P.J. Kostense, and B.Z. Alizadeh Interleukin-1β receptor antagonist gene polymorphisms in ankylosing spondylitis Rheumatology 41 2002 1419 1423
10. W.P. Maksymowych, J.P. Reeve, J.D. Reveille, J.M. Akey, H. Buenviage, and L. O'Brien High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry Arthritis Rheum 48 2003 2011 2018
11. A.E. Timms, A.M. Crane, A.M. Sims, H.J. Cordell, L.A. Bradbury, and M.R. Abbott-Coyne The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis Am J Hum Genet 75 2004 587 595
12. A.L. Tan, H. Marzo-Ortega, P. O'Connor, A. Fraser, P. Emery, and D. McGonagle Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study Ann Rheum Dis 63 2004 1041 1045
13. H. Haibel, M. Rudwaleit, J. Listing, and J. Sieper Open-label trial of anakinra in active ankylosing spondylitis over 24 weeks Ann Rheum Dis 64 2005 296 298